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Background: Development of additional diagnostic 
strategies for earlier HIV diagnosis are needed as 
approximately 50% of newly diagnosed HIV-infected 
individuals continue to present late for HIV care. Aim: 
We aimed to analyse antimicrobial consumption in the 
3 years preceding HIV diagnosis, assess whether there 
was a higher consumption in those diagnosed with 
HIV compared with matched controls and whether the 
level of consumption was associated with the risk of 
HIV infection. Methods: We conducted a nested case–
control study, identifying all individuals (n = 2,784 
cases) diagnosed with HIV in Denmark from 1998 to 
2016 and 13 age-and sex-matched population controls 
per case (n = 36,192 controls) from national registers. 
Antimicrobial drug consumption was estimated as 
defined daily doses per person-year. We used condi-
tional logistic regression to compute odds ratios and 
95% confidence intervals. Results: In the 3 years pre-
ceding an HIV diagnosis, we observed more frequent 
and higher consumption of antimicrobial drugs in 
cases compared with controls, with 72.4% vs 46.3% 
having had at least one prescription (p < 0.001). For all 
antimicrobial classes, the association between con-
sumption and risk of subsequent HIV diagnosis was 
statistically significant (p < 0.01). The association was 
stronger with higher consumption and with shorter 
time to HIV diagnosis. Conclusion: HIV-infected indi-
viduals have a significantly higher use of antimicro-
bial drugs in the 3 years preceding HIV diagnosis than 
controls. Prescription of antimicrobial drugs in pri-
mary healthcare could be an opportunity to consider 
proactive HIV testing. Further studies need to identify 
optimal prescription cut-offs that could endorse its 
inclusion in public health policies.
Introduction
Despite extensive efforts in healthcare policies, ca 50% 
of new HIV cases in Europe continue to be diagnosed at 
late stages of the disease (CD4+ T-cell count < 350 cells/
μL) and ca 30% present with very late HIV infection 
(CD4+  T-cell count < 200 cells/μL or presenting with an 
AIDS-defining illness (ADI)) [1-3].
Late presentation is associated with higher rates of 
morbidity and mortality, poorer response to antiret-
roviral therapy (ART), incomplete immune recovery, 
increased healthcare costs and increased risk of ongo-
ing HIV transmission [4-11]. Therefore, late diagnosis 
has negative consequences for both the individual and 
society as a whole, some of which are irreversible. In 
the Collaboration of Observational HIV Epidemiological 
Research Europe (COHERE) study, late HIV diagno-
sis was associated with a 6–13-fold increased risk of 
ADI and/or death in the first year after HIV diagnosis, 
depending on the area in Europe [12]. Furthermore, the 
Strategic Timing of Antiretroviral Treatment (START) 
study showed that early diagnosis and ART initiation 
(at CD4+  T-cell count > 500 cells/μL) was associated 
with lower rates of serious ADI and of non-ADI includ-
ing death [7]. Initiation of ART in individuals with very 
high CD4+  T-cell counts (> 750 cells/μL) has also been 
associated with a reduction in rates of ADI, especially 
malignant ADI [4]. Taken together, there is a large body 
of evidence supporting the benefits of identifying HIV 
infection at earlier stages.
A number of medical conditions (so-called indica-
tor conditions) have been associated with an undiag-
nosed HIV prevalence > 0.1% and data from the United 
States (US) and France have shown that HIV testing in 
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conditions above this threshold is cost-effective [13-
15]. European guidelines recommend routine HIV test-
ing in individuals presenting with indicator conditions 
or an ADI, in high-risk groups or in conditions where not 
identifying HIV would adversely affect the management 
of the disease [16-19]. Furthermore, guidelines in the 
United Kingdom (UK) recommend universal HIV testing 
for all adults presenting for care in any healthcare set-
ting in geographical areas with high HIV prevalence, 
defined as > 0.2% [20]. Despite these recommenda-
tions, many missed opportunities for earlier HIV diag-
nosis occur in both primary and secondary healthcare 
[21-23].
Denmark has achieved the target from the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) of 90% diag-
nosis, treatment and undetectability [24]. However, 
ca half of the infected individuals are still diagnosed 
at late stages of the HIV infection and therefore, new 
strategies to deal with this problem are needed.
With data from the Danish HIV Cohort Study, we 
recently found that HIV-infected individuals have fre-
quent contacts with primary healthcare (PHC) in the 3 
years preceding their HIV diagnosis. Consequently, PHC 
could play a major role in earlier detection of occult HIV 
infection [25].
Table 1
Baseline characteristics of the study population, Denmark, 1998–2016 (n = 38,976)
Characteristics
HIV 
 
n = 2,784
Controls 
 
n = 36,192
HIV subgroups
VLHIV
n = 954
LHIV
n = 481
EHIV
n = 1,349
n % n % n % n % n %
Male 2,237 80.4 29,081 80.4 744 78.0 372 77.3 1,121 83.1
Age at HIV diagnosis, median years (IQR) 39 (32–48) 39 (32–48) 43 (36–52) 39 (32–47) 36 (30–44)
Age at study inclusion (years)
18–39 1,478 53.1 19,231 53.1 370 38.8 255 53.0 853 63.2
40–49 727 26.1 9,431 26.1 299 31.3 128 26.6 300 22.2
50–59 381 13.7 4,962 13.7 183 19.2 63 13.1 135 10.0
 ≥ 60 years 198 7.1 2,568 7.1 102 10.7 35 7.3 61 4.5
Danish origina
Yes 2,075 74.5 31,064 85.8 671 70.3 340 70.7 1,064 78.9
No 709 25.5 5,128 14.2 283 29.7 141 29.3 285 21.1
Infection mode
MSM 1,365 49.0 Not recorded 366 38.4 230 47.8 769 57.0
Heterosexually infected 1,029 37.0 Not recorded 442 46.3 178 37.0 409 30.3
PWID 191 6.9 Not recorded 41 4.3 31 6.4 119 8.8
Other/unknown 199 7.2 Not recorded 105 11.0 42 8.7 52 3.9
HCV 267 9.6 Not recorded 77 8.1 38 7.9 152 11.3
Hepatitis B core antibody-positive 397 14.3 Not recorded 163 17.1 79 16.4 155 11.5
CD4+  T-cell count at study, median cells/μL (IQR) 330 (130–540) Not recorded 73 (30–140) 276 (236–310) 541 (430–690)
Viral load at study inclusion, median 
log10 copies/mL (IQR) 4.8 (4.1–5.4) Not applicable 5.2 (4.8–5.9) 4.7 (4.2–5.2) 4.5 (3.7–5.0)
Calendar year of diagnosisb
1998–2003 825 29.6 Not applicable 349 42.3 135 16.4 341 41.3
2004–2009 1,168 42.0 Not applicable 362 31.0 212 18.2 594 50.9
2010–2016 791 28.4 Not applicable 243 30.7 134 16.9 414 52.3
Antimicrobial prescription in the study periodc 2,015 72.4 16,750 46.3 743 77.9 324 67.4 948 70.3
Antibiotics 1,895 68.1 15,973 44.1 688 72.1 304 63.2 903 66.9
Antiviral 353 12.7 736 2.0 172 18.0 55 11.4 126 9.3
Antifungals 382 13.7 1,563 4.3 223 23.4 45 9.4 114 8.5
EHIV: early HIV diagnosis; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IQR: interquartile range; LHIV: late HIV diagnosis; 
MSM: men who have sex with men; PWID: people who inject drugs; VLHIV: very late HIV diagnosis.
a p < 0.01, Pearson’s chi-squared test.
b Presented as row percentages.
c One or more prescriptions of at least one of the antimicrobials included in the study.
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Antimicrobial prescription in PHC is related to the treat-
ment of some of the infectious ADI or indicator condi-
tions such as bacterial infections (recurrent pneumonia, 
sexually transmitted infections (STI)), viral infections 
(herpes simplex, herpes zoster), and fungal infections 
(candidiasis), and its prescription could be regarded as 
a proxy for these conditions. Therefore, the aim of the 
present study was (i) to assess antimicrobial drug pre-
scription (i.e. antibiotics, antivirals, and antifungals) 
in the 3 years preceding the HIV diagnosis compared 
with age and sex-matched controls, and (ii) to assess 
whether consumption of antimicrobials was associated 
with an increased risk of subsequent HIV diagnosis.
Methods
Setting
On 31 December 2017, Denmark had a population of 5.7 
million with an estimated HIV prevalence among the 
adult population of 0.1% [26].
The Danish healthcare system is universally tax-funded, 
guaranteeing free access to healthcare for all citizens 
in Denmark. Antimicrobials can only be obtained with 
a prescription from a physician in primary or secondary 
care or administered during hospitalisation.
Study period
The study was performed from 1 January 1998 to 31 
December 2016.
Data sources
We used the Danish personal identification num-
ber, a unique 10-digit personal identifier assigned to 
all Danish citizens at birth or upon immigration, to 
link individuals in the following national healthcare 
registries:
The Danish HIV Cohort Study
The Danish HIV Cohort Study (DHCS) is an ongoing 
nationwide, prospective, population-based cohort 
study of all HIV-infected patients treated at Danish 
hospitals since 1 January 1995. The cohort has been 
described in detail elsewhere [27]. The DHCS consec-
utively enrols patients newly diagnosed with HIV and 
immigrants with HIV infection. Data are updated yearly.
The Danish Civil Registration System
The Danish Civil Registration System (DCRS), estab-
lished in 1968, is a national registry, which stores infor-
mation on vital status, residency and migration for all 
Danish residents. It is updated daily (Monday through 
Friday). All immigrants registered as living in Denmark 
are included. While undocumented migrants have 
access to healthcare through a temporary registration 
number, they cannot be followed over time through the 
administrative registries [28].
The Danish National Prescription Register
The Danish National Prescription Register (DNPR) col-
lects individual-level data on all medical prescriptions 
Figure 1
Antimicrobial drug prescription in the 3 years before HIV diagnosis, stratified by sex, Denmark, 1998–2016 (n = 38,976)
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Figure 2
Prescription of antimicrobials for cases and controls, by year before HIV diagnosis of the matched case, Denmark, 1998–
2016 (n = 38,976)
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For each antimicrobial class, we categorised the consumption based on different DDD cut-offs. The specific DDD cut-offs used for each 
antimicrobial drug class illustrate the average estimated number of DDD for one standard treatment for the most common infections.
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redeemed at Danish community pharmacies since 1 
January 1995. The registry includes variables related 
to the patient, prescriber, pharmacy and dispensed 
drug. The latter includes date of dispensing, name, 
drug code, anatomical therapeutic chemical classifica-
tion (ATC) code (available to 5th ATC level), number of 
packages, package size, strength, number of defined 
daily doses (DDD) per package, and drug formulation. 
The registry does not contain data on drugs used dur-
ing hospital admission [29].
Design
The study was designed as a case–control study 
nested in the DHCS.
Study population
Cases
From the DHCS, we identified all adults (≥ 18 years) 
in Denmark diagnosed with HIV infection between 1 
January 1998 and 31 December 2016 who had been 
living in Denmark in the 3 years before their HIV diag-
nosis. All cases were stratified as (i) very late HIV 
diagnosis (VLHIV), i.e. CD4+  T-cell count < 200 cells/
μL or presentation with an ADI within 6 months of the 
HIV diagnosis, regardless of the CD4+  T-cell count, (ii) 
late HIV diagnosis (LHIV), i.e. CD4+  T-cell count 200–
349 cells/μL, and (iii) early HIV diagnosis (EHIV), i.e. 
CD4+ T-count ≥ 350 cells/μL or documented seroconver-
sion within the last 12 months, regardless of CD4+ T-cell 
count. Study inclusion was the date of HIV diagnosis.
Population controls
For every HIV-infected individual, we identified 13 age 
and sex-matched population controls from the DCRS. 
We chose this number of controls to secure the statis-
tical power of the analysis. None of the controls had 
been diagnosed with HIV before 31 December 2016. 
All controls had to be alive and living in Denmark in 
the 3 years before HIV diagnosis for the matched case. 
Study inclusion was the date of HIV diagnosis for the 
matched case.
Exposure
Using data from the DNPR, we assessed antimicrobial 
consumption based on all redeemed prescriptions of 
oral antimicrobial drugs in the 3 years before study 
inclusion. The consumption was further expressed as 
DDD per person-year (PY) (for names and ATC codes 
see Supplementary Table S1). Only those drug classes 
prescribed to > 1% of the HIV-infected individuals were 
included for further analysis (beta-lactams, mac-
rolides, fluoroquinolones, tetracycline, antibiotics only 
used to treat urinary tract infections (UTI drugs), antivi-
rals, azoles and nystatin).
For each antimicrobial drug class, we categorised 
the consumption based on different DDD cut-offs. 
These cut-offs were chosen based on clinical crite-
ria as the average estimated number of DDD for one 
standard treatment for the most common infections 
(Supplementary Table S1).
Consumption of each antimicrobial class was assessed 
according to (i) the total DDD/3 PY, in the whole 3-year 
study period before HIV diagnosis and (ii) the percent-
age of patients in each DDD/PY category both per year 
and in the whole 3-year period.
Statistics
For all antimicrobial drug classes, we assessed the 
fraction of cases and controls in each drug consump-
tion group (i.e. category of DDD/PY) as defined above.
To identify exposures associated with risk of sub-
sequent HIV diagnosis, we used conditional logistic 
regression analysis to compare exposure to different 
levels of antimicrobial drug consumption between 
cases and controls, providing an odds ratio (OR) and 
a 95% confidence interval (CI). These exposures were 
estimated both as categorical (DDD categories defined 
above vs no consumption) and as binary variables 
(consumption above different DDD/PY cut-offs vs con-
sumption at or under this level). Based on the rare dis-
ease assumption, these OR were used as estimates of 
the relative risk (RR) of acquiring HIV.
To analyse the trend of increase in consumption of anti-
microbial drugs in the different years before HIV diag-
nosis, we used the Cochran–Armitage test.
As there was a clinical and statistically significant 
interaction between the person’s sex and the risk of 
HIV diagnosis (likelihood ratio test; p < 0.01), we further 
stratified the analyses by sex. In a sensitivity analysis, 
we further stratified the data by HIV subgroup (EHIV, 
LHIV and VLHIV), mode of infection, Danish origin and 
age group (18–39, 40–59 and ≥ 60 years).
Finally, based on the assumption that we would test 
for HIV all exposed individuals within certain cut-offs 
for antimicrobial consumption, we used the fraction of 
exposed controls and cases in the study to estimate 
the percentage of people being tested, the percentage 
being diagnosed and the effectiveness factor [25]. The 
effectiveness factor was calculated by dividing the frac-
tion of cases that would be diagnosed by the fraction 
of controls that would be tested and provided an esti-
mation of how effective the interventions at different 
cut-offs would be compared with testing at random in 
a population with the same demographical pattern as 
our sample. Only a factor > 1 was considered effective.
STATA software (version 14) was used for data analysis.
Ethical statement
The study was approved by the Danish Data Protection 
Agency (journal no 2008–41–1781). Ethics approval 
and individual consent are not required by Danish leg-
islation governing this type of research on HIV-infected 
individuals.
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Results
Baseline characteristics
We identified 2,784 cases and 36,192 controls that ful-
filled the inclusion criteria in the period from 1998 to 
2016. Eighty per cent of cases and controls were male 
and the median age at diagnosis was 39 years (inter-
quartile range (IQR): 32–48). Sexual transmission was 
the main infection route among cases, heterosexual 
for women (80%) and homosexual for men (61%). The 
majority of cases and controls were of Danish origin 
(male cases: 81%, male controls 86%, female controls 
85%), except female cases of whom only 49% were of 
Danish origin. Non-Danish origin, older age and hetero-
sexual transmission route were more common among 
those presenting with LHIV and VLHIV compared with 
EHIV. Although a slight decrease in the fraction of 
VLHIV was observed in recent calendar years, the frac-
tion of LHIV and VLHIV remained high during the period 
2010 to 2016 (16.9% and 30.7%, respectively).  Table 
1  shows additional baseline characteristics of the 
study population. During the 3 years before diagnosis, 
72.4% of cases and 46.3% of controls had at least 
one prescription with any of the antimicrobial drugs 
included in the analysis (p < 0.001) (Table 1). Beta-
lactams and macrolides were the two most frequently 
prescribed antimicrobial drug classes for both cases 
and controls in the study period. For all antimicrobial 
drug classes, we found a substantially higher prescrip-
tion rate in cases than controls. Despite the overall 
higher prescription for women compared with men, this 
trend was independent of sex (Figure 1).
Analysis by antimicrobial drug prescription 
levels
For all analysed antimicrobial drugs, we found a signifi-
cantly higher fraction of cases than controls with a high 
drug prescription based on the predefined DDD levels 
Figure 3
Association between different antimicrobial prescriptions in the 3 years before an HIV diagnosis and the risk of being 
subsequently diagnosed with HIV infection, Denmark, 1998–2016 (n = 38,976)
–
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per PY. While drug prescription in HIV cases increased 
substantially the closer the date was to the HIV diag-
nosis, it remained stable among controls throughout 
the 3 years (Figure 2 and Table 2). This difference was 
statistically significant for beta-lactams, macrolides, 
quinolones, acyclovir, azoles and nystatin (p < 0.01, 
Cochran-Armitage trend test).
We found a statistically significant association between 
the level of prescription of any of the analysed antimi-
crobial drugs and the risk of subsequent HIV diagnosis, 
which increased with a higher level of prescription and 
a shorter time to HIV diagnosis (Table 2).
In order to use estimates that could better translate 
into clinical practice, we analysed the exposure (i.e. 
consumption level) during the entire 3-year period as 
a binary exposure. The different DDD/PY cut-offs were 
based on the average estimated number of DDD for 
one or more treatments for the most commonly treated 
infections; the following results therefore illustrate the 
risk of a subsequent HIV diagnosis that was associated 
with the redemption of at least one treatment as com-
pared with no treatment: beta-lactams (OR = 2.13; 95% 
CI: 1.97–2.30), macrolides (OR = 3.12; 95% CI: 2.87–
3.40), acyclovir (OR = 7.20; 95% CI: 6.29–8.25), azoles 
(OR = 3.25; 95% CI: 2.84–3.72), quinolones (OR = 4.14; 
95% CI: 3.52–4.81), nystatin (OR = 10.55; 95% CI: 8.27–
13.46), doxycycline (OR = 4.61; 95% CI: 3.77–5.65) and 
UTI drugs (OR = 1.80; 95% CI: 1.54–2.09) (Figure 3). We 
found an overall strong and linear association between 
the magnitude of drug prescription and the risk of sub-
sequent HIV diagnosis for all antimicrobial drugs with 
the exception of antibiotics used for UTI. For UTI drugs, 
even a higher cut-off (> 10 vs ≤ 10 DDD) had a low OR 
(2.02; 95% CI: 1.61–2.53). The analysis of the effective-
ness factor showed a statistically significant associa-
tion between targeted screening and subsequent HIV 
diagnosis, confirming how effective the different inter-
ventions would be compared with testing at random 
the whole population. The same analysis including only 
the second and third year before the HIV diagnosis is 
shown in Supplementary Table S2.
Sensitivity analyses
We performed several sensitivity analyses, i.e. strati-
fying results according to sex, age, mode of infection 
and HIV subgroups, for the data with statistically sig-
nificant interactions and/or clinical interest.
Firstly, we observed a similar association for men and 
women, although for most of the drugs, the association 
was significantly higher for men. However, it needs to 
be noted that the number of women in this study was 
small (Figure 4 and Supplementary Table S3).
Secondly, a similar association was found for beta-lac-
tams, macrolides, nystatin, doxycycline and UTI drugs 
irrespective of age and sex, when stratifying for both 
these variables. In contrast, in association with pre-
scription of acyclovir, a much stronger association was 
found for middle-aged men (40–59 years; > 2 DDD/3 PY: 
OR: 13.22; 95% CI: 10.20–17.13). Regarding the pre-
scription of azoles, the association increased with 
increasing age for both men and women. For the pre-
scription of quinolones, the association was strongest 
in younger men (Supplementary Tables S4 and S5).
Thirdly, a stronger association between the prescrip-
tion of antimicrobials and subsequent HIV diagnosis 
was observed for men who have sex with men (MSM) 
than for heterosexuals. This association was most pro-
nounced for macrolides, quinolones and doxycycline 
(Supplementary Tables S6 and S7).
Finally, a strong association was observed for all HIV 
subgroups. Nevertheless, for some antimicrobial drugs 
(macrolides, acyclovir and azoles) a more pronounced 
association was observed for cases presenting with a 
late diagnosis (LHIV and VLHIV) (Supplementary Table 
S8).
Discussion
In this nationwide, population-based nested case–con-
trol study, including 2,784 cases and 36,192 controls, 
we identified significantly higher levels of antimicro-
bial drug prescription for cases than controls in the 3 
years preceding a new HIV diagnosis.
For all antimicrobial drug classes analysed, we found a 
statistically significant association between drug pre-
scription and the risk of a subsequent HIV diagnosis. 
This association paralleled the level of prescription 
(i.e. increase in DDD/PY) and the proximity to the HIV 
diagnosis. The association was independent of age or 
Danish origin (data not shown), but more pronounced 
among men and those presenting with late-stage HIV 
infection. Overall, the prescription of antimicrobial 
drugs during the 3-year period was high for both cases 
and controls (72.4% of cases vs 46.3% of controls), and 
beta-lactams and macrolides were the most frequently 
used antimicrobial classes.
In a recent study [25], we established that HIV-infected 
individuals had frequent contacts with PHC in the years 
preceding the HIV diagnosis. Identifying increased pre-
scription of one of these antimicrobial drugs should 
raise awareness among primary care physicians of a 
potential occult HIV infection. Older age and hetero-
sexual HIV-transmission were associated with late HIV 
diagnosis, probably because the clinical suspicion 
of occult HIV infection in these situations is lower. 
Proactive HIV screening based on a surrogate marker 
such as antibiotic prescription could therefore be 
useful.
Although, we had no information on the disease indica-
tion for the prescriptions in this study, we presume that 
the use of antimicrobial drugs may in many cases rep-
resent a proxy for missed HIV indicator conditions such 
as community-acquired pneumonia (CAP), STI, herpes 
simplex infections or candidiasis. Among MSM, we 
observed a stronger association between macrolides, 
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quinolones and doxycycline use and subsequent HIV 
diagnosis compared with other antimicrobials, and in 
the case of quinolones, particularly among younger 
MSM. Although the controls were not matched for sex-
ual preference, this could indicate that the consump-
tion in these cases was driven by STI, which in itself 
should prompt an HIV test. In addition, we assume that 
acyclovir was used for herpes simplex and zoster virus 
infections and azoles mainly for Candida infections and 
these antimicrobials could therefore serve as proxies 
for indicator conditions. Different clinical indications 
are plausible for beta-lactam and macrolides use; 
however, we suspect that a large proportion may have 
been given for CAP.
Our study provides additional evidence concerning 
missed opportunities for earlier HIV diagnosis, regard-
ing both the identification of indicator conditions and 
the identification of behavioural aspects and risk fac-
tors for HIV infection. These findings support that a 
new targeted strategy is needed to find people with 
undiagnosed HIV infection in the general population 
in order to improve timely diagnosis and avoid new 
onward transmissions.
A recent analysis in Denmark has shown that a large 
percentage of people newly diagnosed with HIV has vis-
ited PHC or even hospitals 2 years before the diagnosis 
without being tested for HIV, although they presented 
with some clear indicator conditions [25,30]. Therefore, 
the strategy suggested in our analysis should be com-
plementary to the mandatory HIV testing in people with 
indicator conditions.
The Centers for Disease Control and Prevention (CDC) 
in the US recommend universal HIV screening at least 
once during adulthood when in contact with any 
healthcare setting. However, this practice has so far 
not been widely implemented [31-33]. Furthermore, the 
individual HIV risk may vary during the lifetime if an 
individual develops new risk practices and one random 
HIV test may not capture the patient when at risk. Our 
data indicate that prescription of some antimicrobial 
drugs, and in particular repeated use over a short time 
interval, could be considered a marker of increased 
risk of occult HIV infection and act as a reminder in 
both primary and secondary healthcare to consider HIV 
testing; this would make the risk assessment a more 
dynamic process throughout the lifespan of sexually 
active adults.
Figure 4
Association between antimicrobial prescription in the 3 years before HIV diagnosis and the risk of HIV diagnosis, stratified 
by sex, Denmark, 1998–2016 (n = 38,976)
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In most European countries with a low HIV prevalence, 
targeted HIV testing is recommended based on identify-
ing indicator conditions and risk groups. Nevertheless, 
many missed opportunities for HIV testing occur in 
these situations despite the existing recommendation, 
as highlighted in previous studies [21,22,34]. Based on 
our results, it seems reasonable to perform an HIV test 
after prescription of acyclovir, azoles, nystatin, doxy-
cline, quinolones and macrolides. Even for women, 
whose risk was lower, the results were still statistically 
significant, although it has to be noted that the num-
ber of women in this study was small. Furthermore, 
recurrent beta-lactam use, where we suggest a thresh-
old above two prescriptions in a 1–2-year period, may 
also be used as an indicator to perform an HIV test. 
The antimicrobial consumption in these situations was 
associated with a high risk of HIV with an OR > 2, both 
in the analysis of the cumulative data for all the 3 years 
before HIV diagnosis and in the analysis including only 
the second and third year before diagnosis. Analysis 
of the effectiveness factor of these targeted prescrip-
tions confirmed how effective the different interven-
tions would be compared with testing at random. 
Given an HIV prevalence of 0.1% in the general Danish 
population, HIV prevalence in these subgroups could 
be estimated at above 0.2% (above 0.4% in the case 
of quinolone, doxycycline, acyclovir and nystatin con-
sumption), which is regarded as a cost-effective strat-
egy [13-15]. The prescription of these antimicrobials 
is an easily recognisable parameter, especially when 
using electronic health records. This might help the 
physician identify individuals at risk, and automatic 
reminders could easily be introduced into the sys-
tem. However, in countries without electronic health 
records, these data may not be so easily available. 
Further studies are needed to confirm if this approach 
is cost-effective.
The main strengths of our study include its design with 
nesting in a well-established nationwide population-
based HIV cohort and access to a well-matched con-
trol group from the population. We had full access to 
Danish registries of high quality, allowing us to look 3 
years back in time from the established HIV diagnosis. 
With the DNPR, we had access to valid, nationwide, 
individual-level data on all dispensed antimicrobial 
prescriptions since 1995. Redemption data have proven 
to be a good proxy for consumption as primary non-
adherence to antimicrobial drugs in Denmark is rare 
(6.5%) and antimicrobial drugs are available only on 
prescription from Danish physicians [35]. Furthermore, 
the DNPR includes information on redeemed rather 
than on issued prescriptions, which constitutes a more 
accurate surrogate measure for actual antimicrobial 
consumption, as around 10% of issued prescriptions 
in Denmark are not subsequently redeemed in the 
pharmacies [29]. Of note, our study includes vulner-
able populations such as people who inject drugs and 
migrants. We show that even though these populations 
probably have risk factors that should have triggered 
an HIV test, they do attend primary healthcare and they 
could be captured by their antimicrobial consumption. 
To the best of our knowledge, this is the first study to 
analyse this.
Our study has some limitations. Some antimicrobial 
drugs (i.e. beta-lactams, macrolides, quinolones and 
doxycycline) may have several indications (e.g. CAP, 
skin infections, UTI, STI). Data on the disease indica-
tion for the drug prescriptions or presence of indicator 
conditions is not available in the DNPR. As a result, the 
DDD cut-offs for each antimicrobial class, were chosen 
based on the average estimated number of DDDs for 
one treatment for the most common conditions, may 
not be entirely correct. However, the same sources of 
data were used for both cases and controls, minimis-
ing differential misclassification. Unfortunately, we 
had no information regarding sexual orientation among 
controls and hence no knowledge of the percentage of 
MSM among controls. Another potential shortcoming is 
that we included only individuals living in Denmark 3 
years or more before HIV diagnosis in the matched 
case. Excluding individuals who emigrated or immi-
grated in this period should, however, not affect our 
results, as we did not observe significant differences 
in antimicrobial consumption between non-Danish and 
Danish cases.
Conclusion
This case–control study nested in the nationwide 
DHCS identified a significantly higher consumption of 
many antimicrobial drugs along the 3 years preceding 
a new HIV diagnosis. The antimicrobial drug consump-
tion was associated with a subsequent risk of HIV diag-
nosis. In many cases, the consumption may represent 
a proxy for an HIV indicator condition and thus would 
clearly identify a missed opportunity for timely diag-
nosis of HIV infection and ART initiation. We suggest 
that antimicrobial drug prescription, a parameter easily 
monitored in electronic medical records, could be con-
sidered as part of the individual risk assessment and 
trigger proactive HIV testing in PHC. Further studies are 
needed to confirm the relevance and cost-benefit of 
such an approach.
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